The India Heart Valves Market is segmented by product type, revealing a dynamic landscape with distinct growth drivers. According to the MRFR report, transcatheter heart valves hold the largest market share, driven by the increasing adoption of minimally invasive procedures. The Indian structural heart devices market, which includes transcatheter heart valves, was estimated at US$ 39 million in 2025. The TAVR procedure has seen significant growth, with over 5,000 procedures performed in India over the last decade.

Major recent developments are accelerating this segment. Medtronic officially launched its supra-annular, self-expanding Evolut FX+ TAVR system in India after receiving CDSCO approval in June 2025. The system features improved coronary access, which is critical for the lifetime management of patients, especially as TAVR is increasingly used in younger patients. Additionally, VitaFlow Liberty® successfully completed its first 22 commercial implantations in India between July and September 2025, bringing a new, electrically retrievable TAVI system to the Indian market.

While transcatheter valves lead in growth, surgical heart valves remain a significant segment. The Indian surgical heart valves market was valued at $100.4 million in 2023. In 2023, the prosthetic heart valves segment was the highest revenue contributor in this category. Notably, surgical heart valves are identified as the fastest-growing segment in the overall market, driven by the continued need for durable, long-lasting solutions for younger patients and those with complex anatomy.

By material type, the market is broadly divided into mechanical valves and tissue (bioprosthetic) valves. The Sree Chitra valve, an indigenously developed mechanical heart valve, has been successfully implanted in close to 200,000 patients with success rates comparable to any other heart valve in the market. However, as the primary cause of heart valve replacement shifts from rheumatic heart disease to degenerative diseases, the need for tissue-based heart valves is expected to increase.

By end-use, hospitals account for the largest share of the market. They are the primary centers for cardiac surgeries, equipped with advanced catheterization labs and surgical suites. The presence of skilled cardiac surgeons and interventional cardiologists is essential for both SAVR and TAVR procedures. As more hospitals establish structural heart programs and TAVR centers of excellence, the adoption of both transcatheter and surgical valves is expected to rise.

The segmentation of the India heart valves market reflects the diverse needs of cardiac patients. Transcatheter valves are rapidly gaining ground for high-risk and elderly patients, while surgical valves remain the gold standard for younger, low-risk patients and those requiring complex repairs. As technology continues to advance, the lines between these segments may blur, with hybrid approaches and next-generation devices offering more options for personalized patient care.